Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption.

By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.

Inclusion Criteria:

• Aged ≥ 18 years old
• Able to comprehend the investigational nature of the protocol and provide informed consent
• Diagnosis of recurrent ovarian cancer

Exclusion Criteria:

• No diagnosis of recurrent ovarian cancer confirmed
• Inability to perform regular electronic reporting
• Patient does not understand, sign, and return consent form

Patients with recurrent ovarian cancer who are actively considering enrolling in a clinical trial for said condition, but have not yet completed enrollment and randomization.